MUT Knockout HAP1 Cell Line

The choice depends on whether you are studying MMUT (methylmalonyl-CoA mutase)'s role as the principal adenosylcobalamin (AdoCbl)-dependent mitochondrial enzyme converting methylmalonyl-CoA to succinyl-CoA or modeling methylmalonic acidemia (MMA). The Knockout line is the standard tool for asking whether MMUT is required for propionyl-CoA metabolism — MMUT functions in the propionate degradation pathway, processing odd-chain fatty acids, branched-chain amino acids (Val, Ile, Met, Thr), and cholesterol-derived propionate into TCA cycle entry. Overexpression is useful for studying MMUT in heterologous expression contexts or for testing disease-associated mutations. For metabolic disease research, the EDITGENE MMUT Knockout in HAP1 enables study of propionate metabolism. MMUT mutations cause isolated methylmalonic acidemia (MMA type mut0 if complete loss, mut− if residual activity) — disease variant rescue enables genotype-function studies. Rescue with wild-type or catalytically-dead MMUT is the standard specificity control. The knockout is valuable for studying MMA-related metabolic pathology, AdoCbl-dependent enzymology, and emerging mRNA therapy (Moderna mRNA-3705 for MMA) mechanism studies.

Primary applications: • Methylmalonyl-CoA accumulation: cellular methylmalonyl-CoA and methylmalonic acid levels by LC-MS to characterize MMUT-dependent propionate metabolism. • MMA modeling: rescue with patient-derived MMUT mutations (e.g., G717V mut0 vs hypomorphic mut− variants) for genotype-function studies of methylmalonic acidemia. • Propionate flux: ¹³C-propionate tracing into succinyl-CoA and TCA intermediates given MMUT-mediated propionate degradation. • mRNA therapy mechanism: mRNA-3705 (Moderna's MMA mRNA therapy) mechanism validation requires MMUT-null target cells to demonstrate therapeutic protein expression. EDITGENE recommends this model for researchers investigating methylmalonic acidemia, B12-dependent enzymology, and emerging mRNA therapeutic development.

Yes. MMUT rescue experiments require attention to mitochondrial targeting and B12 cofactor: • Construct design: use a codon-modified MMUT sequence with a small C-terminal tag (FLAG, HA). MMUT has N-terminal mitochondrial targeting sequence cleaved upon import — N-terminal tags must not disrupt processing. • Catalytically-dead rescue: His-coordinating mutations affecting AdoCbl cofactor binding abolish catalytic activity and serve as the standard specificity control. • MMA disease mutation rescue: patient-derived mut0 (complete loss) versus mut− (residual activity) mutations enable disease severity-function correlation studies. • AdoCbl cofactor consideration: rescue interpretation considers cellular AdoCbl availability — MMACHC-pathway downstream products supply AdoCbl. • Functional readout: rescue should restore methylmalonyl-CoA to succinyl-CoA conversion and reduce methylmalonic acid accumulation. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.